Dermira (NASDAQ:DERM)‘s stock had its “buy” rating reaffirmed by equities research analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, April 2nd, AnalystRatings.com reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price points to a potential upside of 80.83% from the company’s current price. Cantor Fitzgerald also issued estimates for Dermira’s FY2019 earnings at ($5.53) EPS.
The analysts wrote, “. We are reiterating our OW rating and 12 month PT of $20 for DERM shares post its equity raise. The raise gives DERM the funds needed to: 1) continue the commercialization of R&D as well as commercialization of product candidates, including for working capital, capex and other corporate purposes. The next catalyst is likely to be Almirall’s (Not Covered) exercise of its EU option for Lebrikzumab. Also, physicians we have spoken with after the positive Phase 2b Lebrikizumab data underscore a place for it in the market given its safety and efficacy. Finally, we continue to think DERM is an interesting asset in a consolidating space.””
A number of other equities research analysts also recently issued reports on DERM. BidaskClub downgraded Dermira from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 15th. ValuEngine downgraded Dermira from a “hold” rating to a “sell” rating in a research note on Wednesday, January 2nd. Zacks Investment Research upgraded Dermira from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research note on Thursday, January 10th. Finally, Raymond James upgraded Dermira from an “underperform” rating to a “market perform” rating and set a $6.71 price target for the company in a research note on Thursday, January 17th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $17.91.
Dermira (NASDAQ:DERM) last released its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.75) by $0.05. Dermira had a negative return on equity of 309.23% and a negative net margin of 523.25%. As a group, research analysts predict that Dermira will post -5.25 earnings per share for the current year.
In related news, insider Eugene A. Bauer sold 35,000 shares of the business’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $15.00, for a total transaction of $525,000.00. Following the completion of the transaction, the insider now directly owns 43,900 shares in the company, valued at approximately $658,500. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 14.80% of the company’s stock.
Large investors have recently made changes to their positions in the stock. Highland Capital Management LP bought a new position in shares of Dermira during the 3rd quarter valued at approximately $488,000. Man Group plc grew its stake in shares of Dermira by 101.0% during the 3rd quarter. Man Group plc now owns 30,152 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 15,152 shares during the period. AQR Capital Management LLC bought a new position in shares of Dermira during the 3rd quarter valued at approximately $211,000. MetLife Investment Advisors LLC grew its stake in shares of Dermira by 55.6% during the 3rd quarter. MetLife Investment Advisors LLC now owns 28,224 shares of the biopharmaceutical company’s stock valued at $308,000 after acquiring an additional 10,085 shares during the period. Finally, Point72 Asset Management L.P. bought a new position in shares of Dermira during the 3rd quarter valued at approximately $2,871,000. Institutional investors own 69.08% of the company’s stock.
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Recommended Story: What is the float in trading stocks?
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.